Drugs / Lunresertib
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06107868 | Mar 2024 → Oct 2025 overdue | metastatic malignant neoplasm, ovarian cancer, uterine cancer | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05147350 | Aug 2022 → Feb 2025 | neoplasm | Debiopharm International SA | Terminated | No outcome recorded |
| Phase 1 | NCT05147272 | Dec 2021 → Aug 2024 | — | Debiopharm International SA | Terminated | No outcome recorded |
| Phase 1 | NCT04855656 | Apr 2021 → Dec 2027 expected | neoplasm | Debiopharm International SA | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05601440 | Jun 2023 → Dec 2027 expected | female breast carcinoma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05605509 Comparator | May 2023 → Nov 2025 | cancer of unknown primary site | Canadian Cancer Trials Group | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Debiopharm International SA | Regulatory Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination with Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer debiopharm.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Debiopharm International SA | Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination with Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer debiopharm.com ↗ |
| 2025-07-15 | Debiopharm International SA | Released by Repare Therapeutics: Repare Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib debiopharm.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lunresertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04855656 ↗ |
| Known as | (R)-LUNRESERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5199076 ↗ |
| Known as | (R)-RP 6306 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5199076 ↗ |
| Known as | (RAC)-LUNRESERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5199076 ↗ |
| Known as | (RAC)-RP-6306 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5199076 ↗ |
| Known as | RP-6306 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05147272 ↗ |
| Action | Inhibit | “Oral PKMYT1 Inhibitor” NCT04855656 ↗ |
| Modality | Small molecule | — CHEMBL5199076 ↗ |
| Route | Oral | “administered orally” NCT04855656 ↗ |
| Target | PKMYT1 | “Oral PKMYT1 Inhibitor” NCT04855656 ↗ |